RubrYc Therapeutics

RubrYc Therapeutics is dedicated to the development of biotherapeutic candidates optimized for clinical development. RubrYc focuses on improving drug discovery by leveraging proprietary technologies developed by HealthTell and a variety of chemical library resources, applying proprietary machine learning and computational biology solutions to discover epitope-selective mono-specific and bispecific antibodies. Inspired by recent advances in molecular library synthesis, large-scale parallel screening, and computational techniques, RubrYc is paving a new path for information-driven therapeutic antibody discovery. RubrYc achieves a deep understanding of key drug/target interactions and enhances decision-making in the drug discovery process through algorithm training.